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Abstract
Background: The identification of novel genes is critical to understanding the molecular basis of
body weight. Towards this goal, we have identified secretogranin V (Scg5; also referred to as
Sgne1), as a candidate gene for growth traits.
Results: Through a combination of DNA microarray analysis and quantitative PCR we identified a
strong expression quantitative trait locus (eQTL) regulating Scg5 expression in two mouse
chromosome 2 congenic strains and three additional F2 intercrosses. More importantly, the eQTL
was coincident with a body weight QTL in congenic mice and Scg5 expression was negatively
correlated with body weight in two of the F2 intercrosses. Analysis of haplotype blocks and
genomic sequencing of Scg5 in high (C3H/HeJ, DBA/2J, BALB/cByJ, CAST/EiJ) and low (C57BL/6J)
expressing strains revealed mutations unique to C57BL/6J and possibly responsible for the
difference in mRNA abundance. To evaluate the functional consequence of Scg5 overexpression
we measured the pituitary levels of 7B2 protein and PCSK2 activity and found both to be increased.
In spite of this increase, the level of pituitary α-MSH, a PCSK2 processing product, was unaltered.
Conclusion: Together, these data support a role for Scg5 in the modulation of body weight.
Background
Body weight, as with all complex traits, is partially regu-
lated by the coordinate action of individual genes. One
common approach for dissecting the genetics of growth is
the mapping of quantitative trait loci (QTL). In the last
decade numerous human and mouse growth QTL have
been identified [1]; however, while this progress is impor-
tant, few if any of the loci have been unequivocally
resolved to the effects of a single quantitative trait gene
(QTG).
Several studies involving many different mouse inbred
strains have demonstrated an enrichment of growth and
obesity QTL on chromosome 2 [2,3]. In our laboratory,
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the goal of discerning the molecular basis of chromosome
2 QTL segregating between the C57BL/6J (B6), C57BL/6J-
hg/hg (HG) and CAST/EiJ (CAST) strains [4,5]. These
include two congenic strains, B6.CAST-(D2Mit329-
D2Mit457)N(6) (B62D) and HG.CAST-(D2Mit329-
D2Mit457)N(6) (HG2D), constructed by introgressing an
identical congenic donor region, extending from approxi-
mately 75 to 180 Mbp, from the CAST strain onto both B6
and HG backgrounds [4]. HG mice exhibit extreme body
weights without becoming obese due to the high growth
(hg) deletion located on chromosome 10, which elimi-
nates the expression of the suppressor of cytokine signal-
ing 2 (Socs2) gene, a negative regulator of growth
hormone signaling [6]. The purpose of generating the
HG2D and B62D strains was to capture the weight gain 2
(Wg2) QTL [7] and evaluate hypothesized interactions
between Wg2 and hg. After construction, HG2D mice were
not characterized due to reproductive problems, however,
B62D mice displayed significant decreases in growth and
obesity traits [4].
In two follow-up studies it was determined that Wg2 was
actually the result of multiple genes. In the first study, an
F2 cross derived from the HG2D congenic and HG pro-
genitor strain (referred to as the HG2DF2 cross) was used
to identify a strong QTL located at 112 Mbp that decreased
body weight at 6 and 9 weeks of age, but did not affect fat
mass. This QTL partially explained the effects of Wg2 and
was referred to as weight gain QTL 5 (Wg5) [5]. In the sec-
ond study, subcongenic mice derived from the B62D con-
genic (referred to as B62D-3), with a CAST donor region
from 102–115 Mbp, were lighter and leaner due to the
effects of a locus we named Wg2b [8]. Based on their coin-
cident genomic location, Wg5 and Wg2b are likely the
same QTL, however, their differing effects on adiposity
suggest that an interaction with hg may eliminate or
decrease the fat reducing effects of Wg5.
In the current study we have used DNA microarrays and
public genomic databases to investigate the genetics of
expression for genes located within the two congenic
models, HG2D and B62D, to identify candidates for the
Wg5 and Wg2b QTL. Based on its genomic location, dif-
ferential expression and biological function, the most
promising candidate is secretogranin V (Scg5; also referred
to as Sgne1). The protein product of Scg5, 7B2, is a molec-
ular chaperone for prohormone convertase 2 (PCSK2).
PCSK2 is a member of the subtilisin-like proprotein con-
vertase family and many PCSK2-generated peptides are
either directly involved in glucose homeostasis (gluca-
gon) or indirectly contribute to body weight regulation
(α-MSH, CART, and nesfatin-1, to name a few examples).
Knockout of peptide biosynthetic enzymes often result in
mice with body weight phenotypes, most notably the fat/
fat mouse with its inactivating mutation in carboxypepti-
dase E [9]. While the PCSK2 knockout mouse is slightly
runted but otherwise of normal weight [10], an obese
PCSK1 mutant mouse has recently been described which
has lowered levels of the PCSK2 product α-MSH [11],
indicating possible interplay/feedback between the pep-
tide synthesizing enzymes (also suggested by [12]). Scg5
has also been implicated in body weight homeostasis.
Scg5 knockout mice (on a 129/SvEv background) exhibit
a postnatal lethal phenotype in which all mice die by 5
weeks of age (due to intermediate lobe ACTH hypersecre-
tion and rampant corticosteronemia); however, adrenal-
ectomy rescues these animals and reveals a late-onset
obesity phenotype [13]. Collectively, these results point to
potential roles for peptide biosynthetic enzymes, and spe-
cifically for Scg5, in body weight regulation.
Results
Identification of differentially expressed genes in HG2DF2 
mice
To identify differentially expressed genes within the
HG2D congenic donor region that potentially underlie
body weight and obesity QTL, we hybridized whole brain
RNA from non-recombinant HG2DF2 mice (mice inherit-
ing intact cast or b6 congenic haplotypes) from each of the
three F2 genotypes (b6/b6, b6/cast and cast/cast) [5] to Agi-
lent whole genome mouse microarrays. Comparison of
normalized expression values identified 62 genes as dif-
ferentially expressed at a false discovery rate (FDR) of
<0.30 using an additive effects model (Additional File 1).
Fifty-five of the genes (88.7%) were located within the
HG2D congenic region (from approximately 75 to 180
Mbp).
Identification of expression QTL (eQTL) overlapping 
growth and obesity QTL
As confirmation of the microarray results, we next exam-
ined the genetic basis of expression for eleven genes
(Cd44, AI451465, Fmn, Scg5, 2310032D16Rik,
3300001M20Rik, Pak7, Actr5, D930001I22Rik, Sdccag33l
and Rab22a) identified as differentially expressed from the
microarray study (Additional File 1). These genes were
selected for confirmation because they were located near
the peaks of previously identified HG2DF2 body weight
and obesity QTL (Table 1) [5]. Gene expression was meas-
ured in whole brain RNA from 45 recombinant HG2DF2
mice using quantitative PCR. Of the eleven genes, signifi-
cant eQTL were identified for five (AI451465, Scg5,
2310032D16Rik, 3300001M20Rik and Actr5) (Table 1).
Expression of Scg5 is genetically regulated by a single local 
acting QTL in multiple mouse crosses
Based on its close proximity to Wg5 [5], biological func-
tion and magnitude of differential expression, Scg5 was
selected as the highest priority candidate gene. From thePage 2 of 12
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BMC Genetics 2008, 9:34 http://www.biomedcentral.com/1471-2156/9/34microarray analysis, Scg5 was the eighth most signifi-
cantly differentially expressed gene, with an FDR = 0.10,
and its expression was up-regulated by approximately 3.0
fold in non-recombinant cast/cast HG2DF2 mice (Addi-
tional File 1). qPCR analysis in HG2DF2 mice indicated
the expression difference was due to a Scg5 eQTL located
at 55.5 cM (approximately 115 Mbp) mapping with a
maximum LOD score of 16.4 (Figure 1). The eQTL was
primarily additive (a = -0.68 and d = -0.14), with cast alle-
les increasing expression. The eQTL explained 74.1% of
the variation in Scg5 expression. The nearest marker,
D2Mit207 (located at 9.7 cM or 111.8 Mbp), was less than
Table 1: Expression QTL for genes coincident with growth or obesity QTL and differentially expressed in HG2D mice
Gene symbol Mbp eQTL LOD cM Mbp Coincident QTL
AI451465 112.272 9.8 64.0 134 Wg5
Scg5 113.578 16.4 55.5 115 Wg5
2310032D16Rik 132.221 5.5 55.5 115 Fatq1
3300001M20Rik 132.496 3.0 66.5 138 Fatq1
Actr5 158.316 8.6 75.0 155 Fatq1, Fatq2
All eQTL are significant at P < 0.05
Scg5 expression is regulated by a strong local eQTL on chromosome 2 and is coincident with QTL for body weight and body mass index in HG2DF2 miceFi ure 1
Scg5 expression is regulated by a strong local eQTL on chromosome 2 and is coincident with QTL for body 
weight and body mass index in HG2DF2 mice. The plot presents the LOD score profile across the HG2D donor region 
for Scg5 expression, body weight at 9 weeks and body mass index. Genetic positions in centimorgan (cM) are plotted on the x-
axis. The location of Scg5 (113.6 Mbp) is indicated with an arrow.
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Body mass index
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strongly suggesting the variation controlling the differ-
ence in expression was local in nature (eQTL have tradi-
tionally been referred to as cis if the variation affecting
expression lies in the differentially expressed gene as is the
case for Scg5, however, true trans eQTL may also show a
similar behavior. Therefore, we have adopted the use of
the more general local and distant nomenclature recently
proposed by [14]). Importantly, previously identified
QTL for body weight at 9 weeks (Wg5) [5] and body mass
index in HG2DF2 mice (located at 54 cM and 54.7 cM,
respectively) were coincident with the Scg5 eQTL (Figure
1).
To determine the effect of genetic background on tran-
scriptional regulation of Scg5, we performed QTL analysis
with expression data from three different crosses. Two
were analyzed using the GeneNetwork resource for system
genetics [15,16]. The GeneNetwork contains microarray
data on whole brain gene expression in B6 × DBA (BXD)
recombinant inbred (RI) strains [17] and hippocampus
gene expression in B6 × BALB (CXB) RI strains. QTL anal-
ysis for the levels of Scg5 expression revealed strong local
eQTL in both crosses (Figure 2). Scg5 expression was also
found to be under the control of a strong local eQTL using
whole brain expression data from a recently described B6-
ApoE-/- × C3H-ApoE-/- F2 intercross (BXH-ApoE-/- F2) (Fig-
ure 2) [18]. In all three crosses B6 alleles decreased expres-
sion. Additionally, the expression of Scg5 was correlated
with body weight in BXD and CXB mice, but not in the
BXH-ApoE-/- F2 cross (Table 2). Thus, genetic variation
near the Scg5 locus accounts for the majority of variation
in mRNA levels in multiple genetic backgrounds, and
importantly the low-expressing allele is unique to B6.
Transcriptional regulation of Scg5 in B62D-3 F2 mice
Since Scg5 is regulated by a strong local eQTL in HG2DF2
mice (Figure 1) we also expected it to be differentially
expressed in wild type B62D-3 F2 mice. B62D-3 mice are
wild-type with respect to the hg deletion and are congenic
for cast alleles from 102–115 on chromosome 2 in the
region of Scg5 [8]. To confirm differential expression we
measured mRNA levels in mice of all three B62D-3 F2
genotypes (b6/b6, b6/cast and cast/cast). As expected, Scg5
was up-regulated in cast/cast mice by approximately 2.5
fold (Figure 3). Additionally, if differential expression of
Scg5 is causal for Wg5 (in HG2DF2 mice) and Wg2b (in
B62D-3 mice), then its expression must correlate with
growth traits and indeed its expression was significantly
negatively correlated (P < 0.01) with body weight and
obesity in both crosses (Table 2).
Scg5 expression is up-regulated in high growth (HG) mice
If an interaction exists between Wg5 and hg (as has been
hypothesized in [4,7]), it may be mediated via alterations
in Scg5 expression. To determine if expression is altered by
hg, Scg5 was quantified in HG and B6 mice at 3, 4.5 and 9
weeks of age. At all three time points the relative expres-
sion of Scg5 in whole brain was increased in HG mice
(Additional File 2). A suggestive (P < 0.10) 25% increase
at 3 weeks was followed by approximately 40% increases
at 4.5 (P < 0.05) and 9 weeks (P = 0.06).
Identification of Stat5b binding sites in the Scg5 promoter
The hg deletion encompasses three genes; Socs2, Raidd and
Plexin C1 [19]. The extreme growth rate and mature body
size of HG mice (homozygous for the hg deletion) is pri-
marily (if not entirely) due to the absence of Socs2 [6]. In
Socs2-/- mice increased growth is dependent on Stat5b [20].
The DNA sequence required for Stat5b binding has been
well characterized [21].Stat5b is the primary transcription
factor responsible for mediating Gh induced gene expres-
sion changes [22] and a modest increase in its activity has
been identified in Socs2-/- mice [20]. To identify putative
Stat5b binding sites which may be used by Gh (via Stat5b)
to regulate the increase of Scg5 expression in HG mice, we
screened 72.683 Kbp of Scg5 genomic sequence for the
presence of the Stat5b consensus transcription factor bind-
ing site TTCYNRGAA (Y = T or C and R = A or G) [21]. The
sequence included all introns and exons and 10 kbp of 5'
and 3' genomic sequence. In total six consensus sites were
identified (Additional File 2). Interestingly, two tandem
sites in the Scg5 promoter were located between -56 and -
39 (relative to the transcription start site; Additional File
2). The probability that these sites occur by chance is 418,
suggesting they are functional and may mediate the
increased expression of Scg5 in HG mice.
Genomic analysis of the Scg5
It is likely that most polymorphisms giving rise to local
(truly cis) eQTL will reside within promoter or intronic
based regulatory elements [23]. With this in mind, we
analyzed the genomic sequence of Scg5 to identify puta-
tive polymorphisms that may be responsible for the
strong local eQTL. This is important since it could lead to
the discovery of novel modes of Scg5 transcriptional regu-
lation. Based on the eQTL results from multiple crosses,
we hypothesized that two haplotypes should exist in the
genomic region containing the eQTL, one unique to B6
(low expressers) the other shared between CAST, BALB,
DBA and C3H (high expressers). To identify potential
regions, haplotype blocks were identified by downloading
all SNPs within Scg5 from the Mouse Phenome Database
[24,25]. A total of 191 SNPs were identified between
113.571079 and 113.633403 Mbp on chromosome 2
(Additional File 3). This 62.324 Kbp region encompassed
the entire Scg5 coding sequence, promoter, over 5 Kbp
downstream and the 3' end of Arhgap11a, which is located
2.4 kbp upstream of the first Scg5 exon. As predicted, two
haplotype blocks were identified using the HaploviewPage 4 of 12
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A strong local eQTL on chromosome 2 regulates the expression of Scg5 in BXD, CXB and BXH mouse crossesFigure 2
A strong local eQTL on chromosome 2 regulates the expression of Scg5 in BXD, CXB and BXH mouse 
crosses. Mapping of Scg5 expression in A) whole brain from B6 × DBA (BXD) recombinant inbred (RI) mice, B) hippocampus 
from BALB × B6 (CXB) RI mice, and C) whole brain from BXH-ApoE-/- F2 mice. eQTL were identified using interval mapping 
tools available at [15, 16] for BXD and CXB crosses and R/qtl [38] software for BXH-ApoE-/- F2 mice.
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BMC Genetics 2008, 9:34 http://www.biomedcentral.com/1471-2156/9/34software package [26]. Block 1 extended from the begin-
ning of the queried region at 113.571079 Mbp to
113.581978 Mbp (10.899 Kbp) and block 2 spanned
from 113.582743 Mbp to the end of the interval at
113.633403 Mbp (50.660 Kbp) (Additional File 3). Block
1 did not fit the necessary criteria of being unique to B6
(B6 and CAST were very similar across this block), how-
ever, block 2 consisted of three predominant haplotypes,
one unique to B6, one unique to CAST and the other was
highly similar among C3H, DBA and BALB. Although
CAST differed from all other strains across the whole
block, it was much more similar to C3H, DBA and BALB
in the region corresponding to exon 2 and the first two
introns. The haplotype similarities and differences across
both blocks are shown in cladograms in Additional File 4.
Therefore, since the region of haplotype block 2 contains
a haplotype unique to B6 and similar among the other
strains it is likely the genetic variant underlying the eQTL
is located in this region.
None of the SNPs included in the above analysis were
located within the proximal promoter. To comprehen-
Table 2: Correlation between Scg5 expression and body weight in five mouse crosses
Cross Trait Correlation p-value Details
HG2DF2 9 week weight -0.34 0.02 calculated in 45 HG2DF2 mice
B62D-3 6 week weight -0.45 0.01 calculated in 15 non-recombinant B62D-3 mice, 5 of each genotype
B62D-3 9 week weight -0.62 <0.01 calculated in 15 non-recombinant B62D-3 mice, 5 of each genotype
BXD RI Adult body weight -0.53 0.02 calculated in 16 BXD RI and 2 parental strains, phenotype = BXHPublish:10031 [15, 
16]
CXB RI 90 day body weight -0.82 <0.01 calculated in 7 BXD RI and 2 parental strains, phenotype = BXHPublish:10281 [15, 
16]
BXH-ApoE-/- F2 Adult body weight -0.01 0.81 calculated in 255 BXH-ApoE-/- F2 mice
Scg5 expression is up-regulated in B62D-3 F2 miceFi ure 3
Scg5expression is up-regulated in B62D-3 F2 mice. The relative expression of Scg5 is presented for the three B62D-3 
F2 genotypes (b6/b6, b6/cast and cast/cast).
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upstream of the transcription start site (as defined by Ref-
Seq NM_009162) in B6, HG, CAST, BALB, DBA and C3H
mice. Ten SNPs were identified across all six strains (Table
3). In addition, an 11 bp deletion between -432 and -422
(del-432) was identified in DBA, C3H and BALB. This
deletion was previously identified in C3H mice by
Schmidt et al. [27]. Consistent with the above haplotype
analysis, BALB, DBA and C3H shared an identical haplo-
type across the region. CAST was polymorphic at all 10 of
the SNPs (but not del-432) relative to B6 and the other
strains were polymorphic at SNPs -1373, -794 and -659.
Interestingly, CAST mice did not possess del-432, how-
ever, position -432 was polymorphic between B6 and
CAST mice. Therefore, since these four SNPs are unique to
B6, the low Scg5 expressing strain, it is probable that one
(or more) may give rise to the Scg5 eQTL
Up-regulation of Scg5 increases levels of 7B2 protein and 
PCSK2 enzyme activity
To characterize the molecular consequences of Scg5 up-
regulation, the levels of 7B2 protein, Pcsk2 gene expres-
sion, PCSK2 activity, α-MSH and ACTH levels were quan-
titated in B62D-3 F2 mice. The levels of pituitary (pit) 7B2
mirrored the differences in whole brain Scg5 expression in
mice of differing B62D-3 genotype. b6/b6 mice had the
lowest levels with 1.25 ± 0.04 pmol/pit, b6/cast mice fol-
lowed with 1.34 ± 0.04 pmol/pit while cast/cast mice had
the highest levels of 1.55 ± 0.04 pmol/pit (Figure 4). The
difference between b6/b6 and cast/cast mice was highly sig-
nificant (P < 0.01). In addition, the activity of PCSK2 also
increased coincident with Scg5 mRNA abundance and
7B2 protein levels (Figure 4). The difference in activity
between b6/b6 and cast/cast genotypes was 27%. All pair-
wise genotype comparisons were highly significant (P <
0.0001). The distal border of B62D-3 ends at 115 Mbp
and Pcsk2 is located on chromosome 2 at 143 Mbp. There-
fore, the difference in PCSK2 activity could not result from
CAST and B6 allelic differences at the Pcsk2 locus. To rule
out distant-regulation of Pcsk2 in B62D-3 mice we meas-
ured Pcsk2 mRNA levels. No difference in expression was
observed due to B62D-3 genotype (Figure 4). α-MSH and
ACTH are secreted peptides, both products of convertase-
mediated proopiomelanocortin processing in the pitui-
tary. Although PCSK2 activity was increased, no differ-
ences were seen in the tissue levels of either peptide
(Figure 4).
Discussion
In the current study we have demonstrated that transcrip-
tional variation in Scg5 across several inbred strains is
mediated almost entirely by local genetic variation near
the Scg5 locus. More importantly, we have demonstrated
that an increase in Scg5 expression is correlated with
decreases in body weight and obesity in two congenic
mouse models and overexpression results in an in vivo
increase in 7B2 protein levels and PCSK2 enzymatic activ-
ity.
By analyzing the expression of Scg5 in multiple segregat-
ing populations we have conclusively shown that nearly
all of the variation in Scg5 expression is due to a strong
local-acting variant. In all four crosses surveyed, the eQTL
accounted for over 75% of the variation in Scg5 expres-
sion. Haplotype analysis using a recently generated high-
density SNP collection indicated that the most probable
location for the Scg5 local eQTL quantitative trait nucle-
otide was the promoter through the first four exons/
introns. In the Scg5 promoter, four polymorphisms
unique to the high-expressing strains were discovered. Of
particular interest is del-432, an 11-bp deletion present in
all strains except B6 and CAST. Although the deletion is
absent in CAST, these mice are polymorphic at position -
432 (possessing a T allele instead of the C allele in B6). It
is tempting to speculate that this region is important for
binding of a transcriptional repressor and that -432 is a
key nucleotide.
Table 3: Scg5 promoter polymorphisms in C57BL/6J, C57BL/6J-hg/hg, BALB/cByJ, C3H/HeJ, DBA/2J and CAST/EiJ strains
Strain Scg5 
exp.
-2475 
(A/G)
-2445 
(A/C)
-1540 
(A/G)
-1373 
(A/G)
-1095 
(G/C)
-904 (G/
T)
-794 (G/
A)
-659 (A/
G)
-432 (C/
T)
del-432 -306 (A/
C)
C57BL/6J LOW AA AA AA GG GG GG GG AA CC + AA
C57BL/
6J-hg/hg
LOW AA AA AA GG GG GG GG AA CC + AA
BALB/
cByJ
HIGH AA AA AA AA GG GG AA GG del del N/A
C3H/HeJ HIGH AA AA AA AA GG GG AA GG del del N/A
DBA/2J HIGH AA AA AA AA GG GG AA GG del del N/A
CAST/EiJ HIGH GG CC GG AA CC TT AA GG TT + CC
SNPs are numbered based on position upstream from transcription start site as defined by RefSeq NM_009162,. SNPs with genotypes in bold italics 
segregate low expressers and high expressers. +, deletion not present in these strains; del, deletion is present in these strains; N/A, genotypes for -
306 were not determined for strains with deletion due to the forward primer sequence overlapping the deletion.Page 7 of 12
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BMC Genetics 2008, 9:34 http://www.biomedcentral.com/1471-2156/9/34The action of Scg5 overexpression on body weight may
represent either a direct effect of 7B2 or an indirect effect
mediated by PCSK2-generated peptides. In this regard, it
should be pointed out that it is not yet clear that 7B2 is
always regulatory for PCSK2-mediated peptide produc-
tion. A recent paper showing that the varying 7B2 levels
synthesized by two different mouse strains are associated
with differential production of glucagon [27] supports the
notion that 7B2 levels do modulate in vivo peptide pro-
duction, possibly by regulation of PCSK2 activity. How-
ever, our present results do not support an obligatory
association of increased peptide production by increased
PCSK2 activity, since we observed no changes in pituitary
α-MSH, a PCSK2 product, even though tissue PCSK2
activity increased. While two studies have shown that
introduction of 7B2 into cells which lacks all 7B2 produc-
tion facilitates the generation of PCSK2-mediated pep-
tides [28,29], when cells already express some Scg5,
additional 7B2 introduction does not always increase
peptide production. An example is the transfection of Scg5
into AtT-20-PC2 cells, a neuroendocrine cell line which
endogenously produces 7B2. The additional increase of
7B2 neither increases α-MSH production nor facilitates
any other PCSK2-mediated peptide cleavage examined to
date [30] and SNL and IL, unpublished results). Presuma-
bly other factors, possibly cell- or tissue-specific, can over-
ride any effects of additional Scg5 expression to limit the
total amount of peptide made. In this regard it is impor-
tant to note that we measured PCSK2-mediated peptide
production only in pituitary; PCSK2/7B2 effects may also
occur in other tissues more intimately involved in energy
homeostasis, such as the hypothalamus.
If the action of 7B2 on body weight homeostasis is not
mediated via generation of PCSK2-mediated peptides,
then it may result from a direct effect of 7B2 itself. It is cur-
rently impossible to speculate on the mechanism for this
effect; however, this interesting pan-neuronal protein may
have many unexplored roles. A recent paper describes the
association of human neuroblastomas with the epigenetic
7B2 levels and PCSK2 activity are increased in B62D-3 F2 mice overexpressing Scg5Figure 4
7B2 levels and PCSK2 activity are increased in B62D-3 F2 mice overexpressing Scg5. A) 7B2 pituitary levels, B) 
Pcsk2 mRNA expression, C) PCSK2 activity, D) pituitary α-MSH and E) pituitary ACTH levels in the three B62D-3 F2 geno-
types (b6/b6, b6/cast and cast/cast).
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expression was associated with increased tumor forma-
tion, suggesting that 7B2 expression may contribute to the
maintenance of neuronal differentiation.
Although we have provided several lines of evidence sup-
porting the role of Scg5 in body weight regulation, that is
in agreement with a prior knockout study demonstrating
an increase in body weight in the absence of Scg5 [13], we
have not demonstrated a direct causal link between Scg5
overexpression and reductions in body weight. It is possi-
ble that the local eQTL, regulating Scg5 expression, is in
tight linkage with the actual causal variant(s) responsible
for Wg5. It will take additional studies, such as generating
a Scg5 transgenic mouse to confirm its involvement in
body weight regulation.
In the current study we have shown that in addition to the
effects of the strong eQTL, Scg5 is up-regulated in HG
mice, suggesting that this gene is responsive to growth
hormone signaling. As discussed above, HG mice lack
expression of Socs2. The absence of Socs2 leads an increase
in the activity of Stat5b in Socs2-/- mice a factor which
mediates the transcriptional effects of growth hormone
[20]. The molecular and physiological consequences of
this increase are unclear; however, it should be noted two
previous studies have provided data supporting an inter-
action between hg and chromosome 2 QTL [4,7]. It is pos-
sible that the increase in Scg5 expression underlies this
interaction.
Conclusion
We have provided data to support Scg5 as a candidate
gene for body weight homeostasis. Further, our results
show that expression of the Scg5 gene product, 7B2, is
likely to be controlled by strain-dependent promoter pol-
ymorphisms and that this difference in expression leads to
an increase in the enzymatic activity of PCSK2. The mech-
anism by which increased 7B2 levels contribute to body
weight is unclear as yet, but may represent a PC2-inde-
pendent effect of this widely-expressed neuroendocrine
gene.
Methods
Mice
Phenotypic and gene expression data were generated from
two inbred strains (B6 and HG [32]), a subcongenic strain
(B62D-3 [8]) and two congenic-derived intercrosses
(HG2DF2 [5] and B62D-3 F2 [8]). In addition, Scg5
sequence data were collected from four inbred strains
C3H/HeJ (C3H), DBA/2J (DBA), BALB/cByJ (BALB) and
CAST and Scg5 expression data were obtained from three
additional crosses not produced in our laboratory, the
BXD RI, CXB RI and BXH-ApoE-/- F2 [16,18]. All animal
protocols were managed according to the guidelines of
the American Association for Accreditation of Laboratory
Animal Care (AAALAC).
Microarray gene expression analysis in whole brain RNA 
from non-recombinant HG2DF2 mice
Total RNA was isolated using TRIzol reagent (Invitrogen)
from homogenized whole brain samples. Whole brain
total RNA from four male non-recombinant (hg/hg, hg/
cast or cast/cast across the entire congenic interval) mice
was used for microarray analysis. Two samples from each
genotype were labeled with each dye (Cy3 or Cy5) using
the Agilent Low RNA Input Fluorescent Linear Amplifica-
tion Kit (Agilent Technologies). Samples were hybridized
on the Mouse Whole Genome Oligo Microarray (Agilent
Technologies) using an incomplete loop design. Using
two arrays, two hg/hg samples (one labeled with Cy3 and
the other Cy5) were hybridized with two reciprocally
labeled cast/cast samples (i.e. hg/hg Cy3 was hybridized
along with cast/cast Cy5). Four additional arrays were used
for the other two genotype combinations (hg/hg vs. hg/cast
and cast/cast vs. hg/cast). TIFF images were obtained using
the Agilent DNA Microarray Scanner BA (Agilent Technol-
ogies) and intensities were measured with the accompa-
nying Feature Extraction Software. Intensities were
normalized by linear and LOWESS regressions and back-
ground corrected by subtracting the trend of minimum
intensities along the surface of the slide. Data were then
analyzed with the maanova package [33-35] from the Bio-
conductor suite for R [36]. Genes were tested both for
additive and dominance effects by setting the appropriate
contrasts in the mixed model yijkl = Dyei + Arrayj + Geno-
typek + Errorijkl where Dye and Genotype are fixed and
Array and Error are random effects. P-values were cor-
rected for multiple comparisons using an FDR transfor-
mation [37].
Expression QTL analysis
Duplicate qPCR reactions were carried out with 25 ng of
cDNA using ABI Gene Expression Assays (Applied Biosys-
tems) for each gene on the Applied Biosystems 7500 Fast
Real-Time PCR System (Applied Biosystems). The ABI
Gene Expression Assays were as follows: AI451465,
Mm00505280_m1; Fmn, Mm00439021_m1; Scg5,
Mm00486077_m1; Cd44, Mm01277160_m1;
2310032D16Rik, Mm00512140_m1; 3300001M20Rik,
Mm00558305_m1; Pak7, Mm00556184_m1; Actr5,
Mm00615134_m1; D930001I22Rik, Mm00557752_m1;
Sdccag33l, Mm01248119_m1, Rab22a,
Mm00508287_m1; and Pcsk2 Mm00500981_m1. Sdha
(succinate dehydrogenase complex, subunit A, flavopro-
tein (fp)) and Gus (beta glucuronidase) were used as
endogenous control genes. They are not located in the
congenic region (Sdha is on MMU13 at 70.4 Mbp and Gus
is on MMU5 at 129.2 Mbp) and both are common, stably
expressed control genes. The control corrected expressionPage 9 of 12
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gene) - Ct ((Sdha Ct + Gus Ct)/2). These measurements
(ΔCt) were then subjected to interval mapping using the
"scanone" function of R/qtl [38]. Mouse age, litter size
and dam's parity were used as additive covariates. The "fit-
qtl" function was used to estimate genetic effects and per-
cent variance explained.
qPCR in B62D-3 and HG mice
qPCR reactions for Scg5 and Pcsk2 were performed in
B62D-3 mice as described above. The expression of each
target gene was determined using the expression, 2-ΔCt,
where ΔCt = Ct (target gene) - Ct (control gene). These val-
ues were analyzed with SAS using a linear model that
included the fixed effects of genotype [39]. The expression
of Scg5 was also measured in whole brain from five HG
and B6 mice at 3 WK, 4.5 WK and 9 WK. qPCR was carried
out as described above and Sdha normalized expression
levels (2-ΔCt) were calculated for each sample. These values
were analyzed with SAS using a linear model that
included the fixed effects of strain, age and strain by age
interaction [39]. The mean values for HG at each age were
then scaled to B6 expression levels.
Scg5 promoter sequencing
PCR amplicons (Additional File 5) covering approxi-
mately 2500 bp upstream of the Scg5 transcriptional start
site were sequenced from the B6, HG, CAST, BALB, DBA,
and C3H strains. PCR amplified fragments were gel puri-
fied using the Qiagen QIAquick gel extraction kit and
sequenced at the High-Throughput Genomics Unit at the
University of Washington.
PCSK2 Enzyme Assays
All of the following extraction steps were performed at
4°C. Pituitaries were briefly sonicated in 100 mM sodium
acetate, pH 5.0, and 1% Triton ×-100 in the presence of a
protease inhibitor cocktail composed of 1 μM pepstatin, 1
μM trans-epoxysuccinic acid (E-64), and 1 mM phenyl-
methanesulfonyl fluoride (PMSF). The extracts were cen-
trifuged for 2 min at 15,000 × g. The supernatants were
used for PC2 enzyme assays. The assay for PC2 was carried
out in triplicate in 96 well polypropylene microtiter plates
using 10 μl of each sample in a total volume of 50 μl con-
taining 200 μM fluorogenic substrate, pyr-Glu-Arg-Thr-
Lys-Arg-methylcoumarinamide (MCA) as a substrate and
100 mM sodium acetate buffer (pH 5.0) containing 5 mM
CaCl2, 0.5% Triton ×-100 in the presence of a protease
inhibitor cocktail above with the addition of 0.14 mM
tosyllysyl chloromethyl ketone (TLCK) [40]. The activity
was also separately measured in the presence of 1 μM 7B2
CT peptide, a specific inhibitor of PC2 [40]. The fluores-
cent product MCA was measured with a Fluoroscan Ascent
plate fluorometer. The amount of released product was
calculated by reference to the fluorescence of the free MCA
standard and is given in fluorescence units (FU) per
minute, in which one FU corresponds to 5.33 pmol of
MCA. These values were analyzed with SAS using a linear
model that included the fixed effects of genotype [39].
7B2 Radioimmunoassays
Pituitaries were homogenized by sonication in 250 μl of
ice-cold 0.1 N HCl. The samples were stored frozen,
thawed, and centrifuged for 15 min at 13,000 rpm
(17,383 × g) at 4°C. The supernatant was lyophilized and
resuspended in 0.5 ml of radioimmunoassay (RIA) buffer
(100 mM sodium phosphate, pH 7.4, containing 0.1%
heat-treated BSA, 50 mM NaCl, and 0.1% sodium azide).
All samples were stored frozen at -70°C until use. For 7B2
assays, 50 μl of pituitary samples were subjected to assay
in duplicate. The polyclonal antiserum against 7B2
(LSU13BF), directed against residues 23–39 of 7B2 [30],
was used to detect 7B2. 125I-labeled 7B2 was prepared by
the chloramine-T method originally described by Hunter
and Greenwood [41] RIAs were carried out according to
protocols described previously [42]. Samples were incu-
bated with 10,000 cpm of iodinated peptide and the
appropriate dilution of rabbit antiserum in a final volume
of 300 μl at 4°C overnight. To separate the antibody-
bound labeled peptide from the unbound labeled pep-
tide, 1 ml of 25% polyethylene glycol and 100 μl of 7.5%
carrier bovine γ-globulin (in PBS) were added. The sam-
ples were vortexed, kept on ice for 30 min, and then cen-
trifuged for 20 min at 3,000 × g at 4°C using a Sorvall
RT6000B refrigerated centrifuge. The supernatant was
aspirated, and the radioactivity in the pellets was deter-
mined. These values were analyzed with SAS using a linear
model that included the fixed effects of genotype [39].
α-MSH and ACTH assays
10 μl of a 1/200 dilution pituitary sample in RIA buffer
were subjected to assay in duplicate. The polyclonal anti-
α-MSH antiserum was commercially purchased from
Chemicon (Temecula, CA). α-MSH assays were per-
formed as described above. ACTH assays were carried out
using the two-site Nichols human ACTH1–39 assay kit
(Nichols Institute, San Juan Capistrano, CA). The 125I-
ACTH antibody used in this kit is directed towards both
N-terminal and C-terminal regions of intact ACTH mole-
cule and does not recognize ACTH cleavage products.
These values were analyzed with SAS using a linear model
that included the fixed effects of genotype [39].
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